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ABSTRACT
Results from clinical diagnostic microbiology laboratories taking part in the UK National Quality
Assessment Service (UK NEQAS) scheme for Mycobacteria Culture between 1993 and 2003 were
evaluated and assessed to determine whether the perceived increase in the use of rapid methods is
improving time-to-positive reporting of results. Four simulated sputum specimens containing
mycobacteria in mixed cultures with normal commensal organisms were distributed three times a
year. Participating laboratories were required to report on the presence of ‘mycobacteria’ and on the
time required to obtain a positive result. The overall level of performance with the mycobacteria culture
external quality assessment specimens remained consistently high, with an average success rate of 94%
over 10 years. The mean time-to-positive decreased from 24 to 17 days during the previous 8 years. A
survey questionnaire, circulated in 2002, addressed the use of continuous automated mycobacterial
liquid culture (CAMLiC) and molecular methods. The increase in the use of rapid culture methods for
the detection of Mycobacterium tuberculosis has resulted in an overall reduction in time-to-positive data
reported by participants, and has provided an indication of participants’ ability to meet the 21-day target
recommended by the CDC for the detection and identiﬁcation of M. tuberculosis.
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INTRODUCTION
The UK National External Quality Assessment
(EQA) Service for Microbiology (UK NEQAS) is a
well-established comprehensive quality assurance
organisation for clinical diagnostic microbiology
laboratories in the UK and other countries [1,2]. As
part of this service, simulated clinical specimens
are prepared in the organising laboratory (Quality
Assurance Laboratory (QAL), London, UK) and
despatched to participating laboratories, which
then examine these specimens and report their
results to the QAL. The service covers a wide
repertoire of microbiological tests, including cul-
ture for mycobacteria. Four simulated sputum
specimens are distributed to participating laborat-
ories three times a year. Participants are required to
report only on the presence of ‘mycobacteria’ to
obtain a fully correct score, as many laboratories
lack the expertise to identify these bacteria to
species level, and referral to a reference centre is the
preferred option [3–6]. Results are recorded for
participants reporting to the species level, but
scoring is unchanged. Participants are also asked to
report the time required to obtain a positive result.
Participants are provided with an analysis follow-
ing each distribution of specimens, showing both
individual and overall performance of participants
within their own country, and within all countries.
MATERIALS AND METHODS
In total, 355 laboratories currently participate in the Mycobac-
terium culture scheme, of which 186 are in the UK and 169 are in
other countries, namely, Austria, Belgium, Iceland, Ireland,
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Finland, Gambia, Greece, Hong Kong, Israel, Italy, Macau, The
Netherlands, Norway, Portugal, Slovenia, South Africa,
Sweden, Switzerland, Tanzania and Turkey. In 1993 there were
246 participants, of which 209 were in the UK and 37 were in
other countries. Strains ofMycobacterium were provided by the
Mycobacterium Reference Laboratories (MRLs) in Cardiff, New-
castle and Dulwich, UK, and included isolates from recent
infections and isolates referred for conﬁrmatory testing. Resist-
ant strains of Mycobacterium tuberculosis were not used, in the
interests of health and safety. The Mycobacterium spp.
distributed were M. avium-intracellulare (n = 1), M. bovis
(n = 1), M. chelonei (n = 1), M. fortuitum (n = 1), M. kansaii
(n = 3), M. malmoense (n = 1) and M. tuberculosis (n = 101). The
simulated sputum specimens, which consisted of freeze-dried
cultures of mycobacteria with commensal organisms, were
distributed to all participants. Specimens that contained com-
mensal ﬂora were included occasionally in order to challenge
the efﬁcacy of decontamination procedures. The quality of the
specimens was checked before and after distribution to partic-
ipants by the QAL and at least one reference laboratory.
Between 35 and 40 (no less than 10%) vials selected randomly
were processed for culture to ensure viability and to exclude
contamination. The lyophilised matrix was considered unsuit-
able for the preparation of smears for screening for atypical
acid-fast bacteria, as the quality of the resulting smears was
variable (a separate scheme is organised for detection of
atypical acid-fast bacteria). Within each distribution, ﬁve sets of
specimens from selected participants were returned to the
QAL, where theywere examined to exclude deterioration of the
specimen between preparation and receipt by the participants.
Specimens were labelled and packed in accordance with UK
and, where appropriate, international regulations for transport
and postage of infectious materials.
Information supplied to participants
Documentation accompanied each distribution, informing
participants of the type of specimen, the examination required,
and the hazards associated with the specimens. Participants
were asked to return results within 10 weeks to the QAL.
Following assessment and scoring of the results at the QAL, a
summary of performance was reported to participants.
Scoring scheme
The scoring scheme used to assess results was the same in
principle as that used in other schemes [7]. A score of ‘2’ was
allocated for a completely correct result (i.e., correct reporting
to species level, or correct reporting to the genus level with
referral of the isolate to a reference laboratory for conﬁrma-
tion), as well as for a negative result for specimens containing
commensal ﬂora only. A partially correct result was allocated a
score of ‘1’ (i.e., correct reporting to the genus level, but failure
to refer strains for full identiﬁcation). A score of ‘0’ was
allocated for an incorrect result (e.g., a false-negative result),
and a score of ‘) 1’ was allocated for the reporting of
unexpected pathogens, including false-positive results.
Questionnaire
A questionnaire requesting information on the methods used
by participating laboratories, focusing on liquid culture
systems and molecular methods, was distributed in 2002.
RESULTS
Results obtained by participating laboratories
with specimens distributed
The percentages of laboratories obtaining fully
correct results with specimens containing myco-
bacteria were 82–97% for M. tuberculosis (Fig. 1)
and 82–96% for mycobacteria other than M. tuber-
culosis (MOTT) (Fig. 2). With three successive
specimens containing M. kansasii, the percentages
of participants reporting the correct species were
8% in 1995, 11% in 1998, and 19% in 2002. For other
species, the percentages were:M. fortuitum in 1995,
6%;M. chelonae in 1999, 6%;M. avium-intracellulare
in 2002, 24%; and M. bovis in 2003, 18%. Of those
laboratories that attempted identiﬁcation to the
species level, the percentages reporting an incor-
rect species were £ 1% for all three specimens
containingM. kansasii, 3% forM. fortuitum, 4% for
M. chelonii, 2% forM. avium-intracellulare, and 11%
for M. bovis. During the distribution period,
between 2% and 10% of laboratories had false-
positive results for specimens with commensal
ﬂora only.
Time-to-positive reporting
Laboratories were ﬁrst requested to report the time
required to provide a positive report in 1994. Data
concerning the number of weeks elapsed were
collected with each specimen. More recently, par-
ticipants were requested to report time required to
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Fig. 1. Mean percentage of laboratories with fully correct
results in successive EQA specimens containing Mycobac-
terium tuberculosis. Total percentage fully correct is the
mean performance measured over all specimens distri-
buted within the same year. AAFB, atypical acid-fast
bacteria.
Walton et al. External quality assessment for mycobacteria culture 1017
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 1016–1021
provide a positive result in days rather thanweeks,
reﬂecting the general trend towards faster report-
ing; an analysis is shown in Table 1.
Questionnaire
A questionnaire requesting details of the methods
used was distributed in February 2002 to 351
participating laboratories; 264 were returned, a
response rate of 77%. A further ﬁve laboratories
returned the questionnaire, indicating that they
were no longer performing culture for Mycobacte-
rium on clinical specimens. Reasons for this change
in procedure, where indicated, included refurbish-
ment of containment level 3 facilities and recent
withdrawal of aMycobacterium culture service.
Number of specimens examined annually
The numbers of specimens processed by respond-
ents per year are shown in Table 2. A signiﬁcant
proportion of respondents (22%) did not state the
number of specimens examined annually. Of the
remainder, 90% examined £ 5000 specimens ⁄ year
(median, 2000). Of the 10% of respondents exam-
ining > 5000 specimens ⁄ year, seven examined
> 10 000 specimens.
Participants were asked to state the types of
clinical specimens examined for mycobacteria. All
264 respondents examined sputum and broncho-
alveolar lavage specimens for mycobacteria, 99%
examined urine specimens, 94% examined cere-
brospinal ﬂuid, 50% examined blood cultures,
91% examined tissue, 97% examined pus and
other aspirated ﬂuids, and 11% examined spec-
imens categorised as ‘other’. Reports included in
the ‘other specimen’ category were received from
21 laboratories examining faeces for mycobacte-
ria, six examining wound swabs and ﬁve exam-
ining water and environmental samples.
Methods used for detection or identiﬁcation of
mycobacteria
Overall, 80 (30%) respondents used direct ampli-
ﬁcation test methods on clinical specimens. In-
house ampliﬁcation tests were performed by
seven laboratories; 33 laboratories used Gen-
Probe MTD (Gen-Probe, San Diego, CA, USA)
and 28 used AMPLICOR MTB (Roche Molecular
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Fig. 2. Percentage of laboratories with completely correct
results in four successive specimens containing mycobac-
teria other thanMycobacterium tuberculosis (MOTT) and one
containing Mycobacterium bovis. When the number of
specimens containing an MOTT strain was more than
one, performance is expressed as the mean: for M. fortui-
tum, n = 1; for M. kansasii, n = 3; for M. chelonae, n = 1; for
M. avium-intracellulare, n = 2; and for M. bovis, n = 1.
AAFB, atypical acid-fast bacteria.
Table 1. Time-to-positive reporting
Days to positive reporta
Cumulative percentage of participants and
modal period required to report a positive
result
1995 1998 2002
14 15 46 56
21 55 65 83
28 87 76 93
> 28b 96 96 97
Modec 28 days 21 days 16 days
aTime required by participants for a positive report, for all specimens examined.
The data displayed are the mean time-to-positive report periods accumulated for all
specimens in the same year.
bThe maximum number of positive (correct) reports submitted and averaged over
all specimens distributed in the same year.
cUntil 2002, participants were asked to report time-to-positive reporting in terms of
weeks rather than days.
Table 2. Number of specimens examined for mycobacteria
per year by the participating laboratories
No. of participating laboratories
handling the indicated no. of
specimens No. of specimens ⁄ year
58 < 1000
69 1000–2000
37 2001–3000
17 3001–4000
4 4001–5000
8 5001–6000
2 6001–7000
0 7001–8000
3 8001–9000
2 9001–10 000
7 > 10 000
57 Not stated
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Systems, Pleasanton, CA, USA). A further 12
laboratories used other methods: two used the
LiPA Mycobacteria kit (Innogenetics, Gent, Bel-
gium); four used the ProbTec ET system (Beckton
Dickinson, Franklin Lakes, NJ, USA); one used
Mycoprep (Abbott Laboratories, Abbott Park, IL,
USA); and ﬁve used the LCx system (Abbot
Laboratories). Eight respondents used more than
one method.
Continuous automated or semi-automated
mycobacterial culture (CAMLiC or SAMLiC)
methods were used by 184 (70%) respondents.
BACTEC 460 TB (Becton Dickinson) was used by
34 respondents, BACTEC 9000 MB by 19 respond-
ents and BACTEC MGIT 960 by 65 respondents.
One respondent used ESP II (Trek Diagnostics,
Cleveland, OH, USA), 35 respondents used
MB ⁄BacT (Organon Teknika ⁄bioMe´rieux, Dur-
ham, NC, USA), and 35 used BacTALERT3D
(Organon Teknika).
Overall, 230 (87%) of the 264 respondents used
conventional culture for the isolation of mycobac-
teria. Of these, 80 used conventional culture
alone, while 150 used both conventional culture
and an automated method. An automated meth-
od alone was used by 34 respondents.
Level of identiﬁcation
The number of respondents referring all suspec-
ted mycobacteria to a reference laboratory with-
out attempting identiﬁcation in-house was 172
(65%); 36 respondents identiﬁed M. tuberculosis
only and referred all other species to a reference
laboratory for further identiﬁcation; 40 identiﬁed
all species of mycobacteria in-house. A further
four respondents identiﬁed some, but not all,
species of mycobacteria in-house and referred the
remainder to a reference laboratory for identiﬁ-
cation. There was no correlation between the
number of specimens examined and the level of
identiﬁcation performed. The number of speci-
mens processed by laboratories performing iden-
tiﬁcation to the species level ranged from
350 ⁄ year to > 12 000 ⁄ year.
Molecular methods used to identify
mycobacterial isolates
Of the 52 (20%) laboratories that employed
molecular detection methods to identify suspected
mycobacteria, 41 used Accuprobe (Gen-Probe),
seven used AMPLICOR MTB, and eight used an
in-house assay ⁄PCR. Other methods were speci-
ﬁed by 27 respondents, including LCx used by 11,
Innolipa (Innogenetics) used by eight, ProbTec
used by two, and Mycoprep used by one. More
than one method was used by 12 respondents.
Methods used for susceptibility testing of
mycobacteria
Susceptibility testing for mycobacteria was per-
formed in-house by 61 (23%) of the 264 respond-
ents; the other laboratories indicated that
mycobacteria were referred to a reference labor-
atory for testing. Solid media were used for
susceptibility testing by 18 respondents, 41 used
an automated method, two used Etest (AB Bio-
disk, Solna, Sweden), and ten used more than one
method. Among the laboratories using an auto-
mated method, BACTEC 460 TB was used by
56%, BACTEC MGIT 960 was used by 34%,
BacTALERT3D was used by 12%, and MB ⁄BacT
was used by one.
DISCUSSION
The overall standard of performance with the
EQA specimens was high, with an average suc-
cess rate of 94% during the previous 10 years.
The percentage of participants reporting identiﬁ-
cation of mycobacteria to the species level dou-
bled from 15% in 1993 to 32% in 2003. This may
reﬂect the fact that non-UK laboratories, which
may be expert or reference laboratories, have
joined the scheme more recently. The reporting of
pathogens from negative EQA specimens is a
recognised occurrence for simulated specimens
from other distribution types [7], but in the case of
mycobacteria culture it is difﬁcult to see how such
reports are generated. The highest percentage of
laboratories reporting a false-positive result (8%)
concerned a specimen distributed in 1999. Of the
23 laboratories claiming to isolate mycobacteria
from this specimen, two also reported a false-
negative result for a positive specimen in the
same distribution, indicating that a transposition
error probably occurred. In a study of false-
positive mycobacteria cultures by Breese et al. [8],
a review of the literature revealed a median false-
positive rate of 3.1% (interquartile range
2.2–10%), as detected by DNA ﬁngerprinting.
False-positive results can be caused by clerical
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error, contamination of clinical equipment, mis-
identiﬁcation and laboratory cross-contamination
[8,9]. Proﬁciency testing programme samples are
a known source of cross-contamination because of
the high bacterial load of many of these speci-
mens [8]. Breese et al. [8] demonstrated how
simple changes in administrative and procedural
processes in their laboratory reduced the rate of
false-positive results from 4% to 0%.
Accurate laboratory diagnosis is essential to
ensure effective clinical management of infected
patients [10–14]. The performance of participating
laboratories with MOTT has improved over time.
In the case of specimens containing MOTT,
M. tuberculosis was the species most often repor-
ted incorrectly. Identiﬁcation of MOTT has
become increasingly relevant in recent years, as
the incidence of these bacteria has increased,
especially in association with patients positive for
human immunodeﬁciency virus or suffering from
AIDS.
Results from the questionnaire concerning
methods indicated that most respondents proc-
essed £ 2000 specimens ⁄ year for mycobacteria
culture. Some duplication in reporting numbers
of specimens processed may have occurred when
the respondent was a reference laboratory that
included referred samples. It is clear that most
respondent laboratories do not use direct ampli-
ﬁcation test methods for the detection of myco-
bacteria in clinical samples but, rather,
commercial assays. The performance characteris-
tics of the available commercial assays include
high speciﬁcity, but the sensitivity is lower than
that of the reference method of liquid culture
combined with solid culture. Therefore, at pre-
sent, direct ampliﬁcation test methods cannot be
used to replace conventional methods for the
diagnosis and management of tuberculosis
[6,10,11,15,16].
Mycobacteria grow fastest in liquid culture,
and automated liquid culture has been shown to
be more sensitive than conventional solid culture
in many studies [10,17,18]. In 1993, the CDC
recommended that a broth culture system should
be used for primary recovery of mycobacteria
[16]. A large proportion (70%) of respondents in
the methods survey indicated that they used a
SAMLiC or CAMLiC method for isolation of
mycobacteria. CDC recommendations concerning
culture go further, stating that a solid culture
medium should be inoculated in addition to
liquid culture. Solid culture media, although
taking longer to detect mycobacteria, have been
shown to have a contamination rate lower than
that of liquid culture systems [10,17,18], and are
useful in the identiﬁcation of many MOTT, in
particular the pigmented species, thereby obvi-
ating the need for expensive molecular typing.
Only 57% of respondents used both conventional
culture and an automated liquid culture system,
thus failing to optimise the laboratory diagnosis
of mycobacteria in accordance with CDC recom-
mendations. Although 30% of respondents used
conventional culture alone, the questionnaire did
not ask respondents to differentiate between
culture on solid and in liquid media; it is therefore
not possible to comment on whether culture on
solid media alone is leading to unnecessary
delays in the reporting of positive cultures. Most
(85%) respondents referred isolates of mycobac-
teria to a reference laboratory for conﬁrmation of
identity or for typing, and 80% referred isolates
for susceptibility testing. According to expert
opinion, this is the preferred option, and several
countries have implemented a national system for
fast-tracking high-priority specimens to promote
the rapid diagnosis of infectious pulmonary
tuberculosis [3,5,11,16,19].
Increasingly, nucleic acid probes are being used
for the identiﬁcation of mycobacteria from posit-
ive cultures [10,11,13–16]. The methods survey
indicated that only 20% of respondents used
molecular techniques to identify isolates of
mycobacteria. Although PCR and other nucleic
acid ampliﬁcation techniques are rapid, speciﬁc
and relatively sensitive, there is a cost implication,
and a certain degree of expertise is required in the
performance of these tests [6,16]. In this connec-
tion, Mostro¨m et al. [20] have highlighted the
need for training and education in molecular
biology.
Optimal therapy for the treatment of mycobac-
terial infection is dependent on the delivery of the
results of susceptibility tests to clinicians as quickly
as possible, and CDC recommendations state that
susceptibility results should be available within an
average of 28 days. Susceptibility testing of myco-
bacteria requires considerable expertise, available
normally only at expert reference laboratories. This
is reﬂected in the results of the methods survey,
which indicated that only 23% of respondents
performed in-house susceptibility testing, while
the remainder referred isolates to a reference
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laboratory. Most (72%) of the respondents who
performed susceptibility testing used an automa-
ted method, indicating the potential for timely
delivery of results.
Overall, the results from the UK NEQAS
scheme indicate that at least those laboratories
that participated in the study are in a good
position to meet the challenge of the CDC recom-
mendation that isolation and identiﬁcation of
mycobacteria should take place within 21 days.
However, these EQA specimens are more likely to
be representative of smear test-positive speci-
mens, containing a bacterial load of ‡ 103 organ-
isms ⁄mL, and therefore do not challenge the
performance of laboratories with specimens con-
taining low numbers of mycobacteria. The
increased use of liquid culture systems has almost
certainly facilitated the early detection of positive
cultures. The rising incidence of tuberculosis and
the impact of MOTT in vulnerable groups have
emphasised the vital role of the laboratory in the
diagnosis of this disease. In facing these chal-
lenges, laboratories must adopt procedures that
allow the rapid and effective detection of myco-
bacteria, but they must also accept the limitations
of the new approaches and the necessity for
robust and routine quality assurance.
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